ROLE OF FDG PET/CT IN HEAD AND NECK SQUAMOUS CELL CANCER; MINI REVIEW

Nosheen Fatima, Sidra Zaman, Areeba Zaman, Farida Shakir, Unaiza Zaman, Anwar Ahmad, Maseeh uz Zaman

Abstract


Abstract: Squamous Cell Carcinoma (SSCC) is the most common head and neck malignancy worldwide. In daily practice, patients with head–neck squamous cell carcinoma (HNSCC) are seen in various clinical settings, requiring a multidisciplinary approach to therapeutic decisions and clinical care. FDG PET/CT plays a well-defined role in the management of these tumors for pre-treatment staging and radiotherapy planning as well as treatment-response assessment and post-therapy follow-up. In this mini-review readers would know about the standard use of FDG PET/CT in the various clinical scenarios of HNSCC.

 

Key Words: Squamous cell carcinoma; Head and neck; FDG PET/CT; staging; response assessment; radiation planning

Full Text:

PDF

References


Machiels J.P, René LC, Golusinski W, Grau CL, Gregoire V. on behalf of the EHNS Executive Board, ESMO Guidelines Committee and ESTRO Executive Board. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2020, 31, 1462–1475. [CrossRef]

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (Version 3.2024). Available online: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed on 21 March 2025).

Arboleda LPA, de Carvalho GB, Santos-Silva AR, Fernandes GA, Vartanian JG, Conway DI, et al. Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Larynx: A Scoping Review of Treatment Guidelines Worldwide. Cancers 2023, 15, 4405. [CrossRef] [PubMed]

ouketsu A, Miyashita H, Kojima I, Sakamoto M, Murata T, Mori S, et al. Comparison of different diagnostic imaging techniques for the detection of bone invasion in oral cancers. Oral Oncol. 2021, 120, 105453. [CrossRef]

Subramaniam, R.M. Quarter Century Positron Emission Tomography/Computed Tomography Transformation of Oncology: Head and Neck Cancer. PET Clin. 2024, 19, 125–129. [CrossRef] [PubMed]

Surti S, Viswanath V, Daube-Witherspoom ME, Conti M, Casey ME, Karp JS. Benefit of improved performance with state-of-the art digital PET/CT for lesion detection in oncology. J. Nucl. Med. 2020, 61, 1684–1690. [CrossRef]

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 328–354. [CrossRef] [PubMed]

Eyassu E, Young M. Nuclear Medicine PET/CT Head and Neck Cancer Assessment, Protocols, and Interpretation. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2024.

Goel R, Moore W, Sumer B, Khan S, Sher D, Subramaniam RM. Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. AJR Am. J. Roentgenol. 2017, 209, 289–303. [CrossRef] [PubMed]

Castaldi P, Leccisotti L, Bussu F, Miccichè F, Rufini V. Role of 18F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol. Ital. 2013, 33, 1–8.

Maghami E, Ismaila N, Alvarez A, Chernock R, Duvvuri U, Geiger J, el al. Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. J. Clin. Oncol. 2020, 38, 2570–2596. [CrossRef] [PubMed]

Barbosa M, Duarte H, Breda E, Monteiro E. PET/CT in the management of metastatic cervical lymphadenopathy from unknown primary site: A seven years retrospective study. Rev. Laryngol. Otol. Rhinol. 2013, 134, 89–94.

ourin CG, Conger BT, Porubsky ES, Sheils WC, Bilodeau PA, Coleman TA. The effect of occult nodal metastases on survival and regional control in patients with head and neck squamous cell carcinoma. Laryngoscope 2008, 118, e1191–e1194. [CrossRef]

Stack BC Jr, Duan F, Subramaniam RM, Romanoff J, Sicks JD, Bartel T, Chen C, Lowe VJ. FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cN0. Otolaryngol Head Neck Surg. 2021 Jun;164(6):1230-1239. doi: 10.1177/0194599820969104. Epub 2020 Nov 24. PMID: 33231504; PMCID: PMC8342266.

Strohl MP, Ha PK, Flavell RR, Yom SS. PET/CT in Surgical Planning for Head and Neck Cancer. Semin. Nucl. Med. 2021, 51, 50–58. [CrossRef]

Castelli J, De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G, et al. Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy. Crit. Rev. Oncol. Hematol. 2016, 108, 40–51. [CrossRef] [PubMed]

Ong SC, Schöder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med. 2008 Apr;49(4):532-40. doi: 10.2967/jnumed.107.044792. Epub 2008 Mar 14. PMID: 18344440.

Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2083-95. doi: 10.1007/s00259-011-1893-y. Epub 2011 Aug 19. PMID: 21853309.

Marcus C, Ciarallo A, Tahari A, Mena E, Koch W, Wahl R, et al. Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria) −Interreader Reliability, Accuracy, and Survival Outcomes. J Nucl Med. 2014;55:1411-1416.

Aiken AH, Rath TJ, Anzai Y, Branstetter BF, Hoang JK, Wiggins RH, et al. ACR Neck Imaging Reporting and Data Systems (NI-RADS): A White Paper of the ACR NI-RADS Committee. (2018) Journal of the American College of Radiology : JACR. 15 (8): 1097-1108. doi:10.1016/j.jacr.2018.05.006 - Pubmed

Abdelaziz TT, Abdel Razk AAK, Ashour MMM, Abdelrahman AS. Interreader reproducibility of the Neck Imaging Reporting and Data system (NI-RADS) lexicon for the detection of residual/recurrent disease in treated head and neck squamous cell carcinoma (HNSCC). Cancer Imaging. 2020 Aug 18;20(1):61. doi: 10.1186/s40644-020-00337-8. PMID: 32811559; PMCID: PMC7437031.

Zaman MU, Fatima N, Zaman A, Zaman U, Tahseen R. Significantly Low Effective Dose from 18FDG PET/CT Scans Using Dose Reducing Strategies: "Lesser is Better". Asian Pac J Cancer Prev. 2016;17(7):3465-8. PMID: 27509993


Refbacks

  • There are currently no refbacks.


© Copyright PJR 2008-